Literature DB >> 8365298

A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma.

A Colacone1, M Afilalo, N Wolkove, H Kreisman.   

Abstract

BACKGROUND: Comparative studies of albuterol by wet nebulizer or metered dose inhaler have tested fixed doses of medications. We compared the dose-response relationship to albuterol by wet nebulization or metered dose inhaler in acute asthma.
METHODS: Randomized, double-blind, placebo-controlled trial. Patients with acute asthma received either albuterol, 0.4 mg, by metered dose inhaler (and holding chamber) or albuterol, 2.5 mg, by wet nebulizer every 30 min until maximal bronchodilation. Forty patients (forced expiratory volume in 1 s [FEV1]: 1.15 +/- 0.43 L; 36 +/- 12 percent predicted) received metered dose inhaler and 40 others (FEV1: 1.08 +/- 0.52 L; 35 +/- 16 percent predicted) received wet nebulization.
RESULTS: Twenty-six patients (65 percent) receiving metered dose inhaler and 30 (75 percent) receiving wet nebulization achieved maximal bronchodilation after two doses. Almost all reached maximal bronchodilation by four doses. The FEV1 improved by 0.72 +/- 0.49 L for metered dose inhaler and 0.68 +/- 0.61 L for wet nebulizer (p = 0.71). A significant linear relationship was seen in both groups (metered dose inhaler r = 0.94; wet nebulizer r = 0.98) between the log dose of albuterol and change in FEV1. About 1/6 the wet nebulizer dose of albuterol was needed to achieve similar response to the metered dose inhaler.
CONCLUSIONS: Albuterol by metered dose inhaler provided similar bronchodilation to that achieved by wet nebulization in patients with acute asthma. The cumulative dose-response technique is applicable in the emergency department setting and is helpful in comparing the relative utility of various bronchodilator regimens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8365298     DOI: 10.1378/chest.104.3.835

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

Review 1.  Severe acute asthma.

Authors:  S Salmeron; M Bard; F X Blanc; A Ellrodt
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Status asthmaticus. From the emergency department to the intensive care unit.

Authors:  N Kenyon; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

3.  Different interpretations of British Thoracic Society guidelines on the emergency self-management of asthma in children.

Authors:  Margaret Graham; Keith Brownlee; Tim Lee; Kate Kubie
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

Review 4.  Asthma exacerbations. 5: assessment and management of severe asthma in adults in hospital.

Authors:  Sarah Aldington; Richard Beasley
Journal:  Thorax       Date:  2007-05       Impact factor: 9.139

5.  Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

6.  Choose better device to treat asthma and put on a happy face.

Authors:  M T Newhouse
Journal:  CMAJ       Date:  1996-08-15       Impact factor: 8.262

Review 7.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

8.  North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management in adults.

Authors: 
Journal:  BMJ       Date:  1996-03-23

Review 9.  Spacer devices for metered dose inhalers.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations.

Authors:  Jason Paris; Edward L Peterson; Karen Wells; Manel Pladevall; Esteban G Burchard; Shweta Choudhry; David E Lanfear; L Keoki Williams
Journal:  Ann Allergy Asthma Immunol       Date:  2008-11       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.